A 3-year follow-up study of atropine treatment for progressive myopia in Europeans
Open Access
- 21 September 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Eye
- Vol. 34 (11), 2020-2028
- https://doi.org/10.1038/s41433-020-1122-7
Abstract
Background Atropine is the most powerful treatment for progressive myopia in childhood. This study explores the 3-year effectiveness of atropine in a clinical setting. Methods In this prospective clinical effectiveness study, children with progressive myopia ≥ 1D/year or myopia ≤ −2.5D were prescribed atropine 0.5%. Examination, including cycloplegic refraction and axial length (AL), was performed at baseline, and follow-up. Outcome measures were spherical equivalent (SER) and AL; annual progression of SER on treatment was compared with that prior to treatment. Adjustments to the dose were made after 1 year in case of low (AL ≥ 0.3 mm/year) or high response (AL < 0.1 mm/year) of AL. Results A total of 124 patients were enrolled in the study (median age: 9.5, range: 5–16 years). At baseline, median SER was −5.03D (interquartile range (IQR): 3.08); median AL was 25.14 mm (IQR: 1.30). N = 89 (71.8%) children were persistent to therapy throughout the 3-year follow-up. Median annual progression of SER for these children was −0.25D (IQR: 0.44); of AL 0.11 mm (IQR: 0.18). Of these, N = 32 (36.0%) had insufficient response and were assigned to atropine 1%; N = 26 (29.2%) showed good response and underwent tapering in dose. Rebound of AL progression was not observed. Of the children who ceased therapy, N = 9 were lost to follow-up; N = 9 developed an allergic reaction; and N = 17 (19.1%) stopped due to adverse events. Conclusion In children with or at risk of developing high myopia, a starting dose of atropine 0.5% was associated with decreased progression in European children during a 3-year treatment regimen. Our study supports high-dose atropine as a treatment option for children at risk of developing high myopia in adulthood.This publication has 41 references indexed in Scilit:
- How does atropine exert its anti‐myopia effects?Ophthalmic and Physiological Optics, 2013
- The complex interactions of retinal, optical and environmental factors in myopia aetiologyProgress in Retinal and Eye Research, 2012
- Retardation of Myopia in Orthokeratology (ROMIO) Study: A 2-Year Randomized Clinical TrialInvestigative Ophthalmology & Visual Science, 2012
- Prevalence of Myopia and its Association with Body Stature and Educational Level in 19-Year-Old Male Conscripts in Seoul, South KoreaInvestigative Ophthalmology & Visual Science, 2012
- Atropine for the Treatment of Childhood Myopia: Safety and Efficacy of 0.5%, 0.1%, and 0.01% Doses (Atropine for the Treatment of Myopia 2)Ophthalmology, 2012
- A Randomized Trial of the Effect of Soft Contact Lenses on Myopia Progression in ChildrenInvestigative Ophthalmology & Visual Science, 2008
- Effects of intravitreally and intraperitonally injected atropine on two types of experimental myopia in chickenExperimental Eye Research, 2007
- Atropine for the Treatment of Childhood MyopiaOphthalmology, 2006
- Effects of Different Concentrations of Atropine on Controlling Myopia in Myopic ChildrenJournal of Ocular Pharmacology and Therapeutics, 1999
- The Effectiveness of 0.5% Atropine in Controlling High Myopia in ChildrenJournal of Ocular Pharmacology and Therapeutics, 1997